Quick Answer
Co-Diagnostics, Inc. reported Total Assets of $24.74 million for the year ending 2025.
- Co-Diagnostics, Inc. showed a decrease of -61.1% in Total Assets from 2024 to 2025.
- This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $467.6 thousand | Q3 2017: $6.05 million | Q1 2018: $3.33 million | Q2 2018: $1.97 million | Q3 2018: $2.71 million | Q1 2019: $6.12 million | Q2 2019: $5.32 million | Q3 2019: $3.81 million | Q1 2020: $20.48 million | Q2 2020: $36.42 million | Q3 2020: $54.65 million | Q1 2021: $81.12 million | Q2 2021: $92.79 million | Q3 2021: $105.36 million | Q1 2022: $171.15 million | Q2 2022: $160.84 million | Q3 2022: $147.84 million | Q1 2023: $117.00 million | Q2 2023: $112.80 million | Q3 2023: $108.68 million | Q1 2024: $86.67 million | Q2 2024: $80.70 million | Q3 2024: $72.38 million | Q1 2025: $55.15 million | Q2 2025: $46.47 million | Q3 2025: $44.74 million.
- Over the full 10 years of available data (2016 to 2025), Co-Diagnostics, Inc.'s Total Assets has grown by 1,809.4%.
- Historical annual values: Fiscal year 2025: $24.74 million | Fiscal year 2024: $63.56 million | Fiscal year 2023: $95.32 million | Fiscal year 2022: $123.09 million | Fiscal year 2021: $160.03 million | Fiscal year 2020: $71.24 million | Fiscal year 2019: $2.22 million | Fiscal year 2018: $1.55 million | Fiscal year 2017: $4.66 million | Fiscal year 2016: $1.30 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: